-+ 0.00%
-+ 0.00%
-+ 0.00%

Bicycle Therapeutics publishes investor presentation on Bicycle molecule platform and oncology pipeline

PUBT·04/20/2026 11:22:34
Listen to the news
Bicycle Therapeutics publishes investor presentation on Bicycle molecule platform and oncology pipeline
  • Bicycle Therapeutics highlighted cash and cash equivalents of USD 628.1 million as of Dec. 31, 2025, with expected financial runway into 2030.
  • Lead program nuzefatide pevedotin (formerly BT5528) advanced into Phase 2 in pancreatic ductal adenocarcinoma.
  • Safety update for nuzefatide pevedotin showed no hemorrhage events to date in 161 patients as of Feb. 9, 2026.
  • Pipeline update outlined radioligand programs targeting MT1-MMP and EphA2, including a 212Pb Bicycle radioconjugate candidate BT1702 in IND-enabling work.
  • Partnered program ION826/AZD4063 targeting phospholamban gene remained in Phase 1 for cardiometabolic disease.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bicycle Therapeutics plc published the original content used to generate this news brief on April 20, 2026, and is solely responsible for the information contained therein.